Scientists at The Lawson Health Research Institute in London are optimistic about the treatment using the Annexin A5 protein, which has been used successfully with patients who have sepsis.
LONDON - A new trial involving 60 patients will be the first in the world to receive treatment for COVID-19 by sepsis using the human protein Annexin A5.
As originally reported by CTV News, Scientists at The Lawson Health Research Institute in London are optimistic about the treatment using the protein, which has been used with patients who have sepsis.
The protein itself has strong ant-inflammatory properties, however in this trial, the researchers are using a manufactured form of the protein.
A large number of critically ill COVID-19 patients develop sepsis around one to two days before developing acute respiratory distress syndrome (ARDS) and organ failure.
The Lawson Health Research Institute has found success in a previous study using the protein in animals. The protein was used to block inflammation and improve organ function when treating sepsis.
If successful in humans, the protein would reduce hyperinflammation associated with sepsis and prevent respiratory and multi-organ failure. It would also prevent blood clots or dying off cells caused by the illness.
The trial is in early stages and further testing will be conducted to determine it's success.
Teenage Driver Charged with Impaired
Thistle Theatre Presents: The Perils of Persephone
CO Awareness Week Underway
Strong Winds Expected for Oxford
Federal Liberals Table Budget
TDMH Celebrates a Year of the RAFT
News Poll: Poppy Campaign Underway
SWPH Confirms Case of Influenza A
Public Input Needed for Woodstock Transit
Interview with the Mayor - November 3rd, 2025
PJHL Recap - Oct 31st to Nov 2nd
Nominations Open for Runway of Stars
Ultimate Burger Battle Begins!
Dodgers Beat Blue Jays in World Series
Impaired Driver Caught in Tillsonburg
Norfolk OPP Investigating Break-and-Enter
PJHL Preview - Oct. 31st to Nov. 2nd
BBBS Volunteers Honoured in London
Poppy Campaign Begins Today
Comments
Add a comment